"Ideal" parathyroid hormone in erythropoietin-stimulating agents-resistant anemia.

ESA‐resistant anemia ESRD PTH bone marrow fibrosis secondary hyperparathyroidism

Journal

EJHaem
ISSN: 2688-6146
Titre abrégé: EJHaem
Pays: United States
ID NLM: 101761942

Informations de publication

Date de publication:
Feb 2022
Historique:
received: 12 09 2021
revised: 24 09 2021
accepted: 27 09 2021
entrez: 18 7 2022
pubmed: 19 7 2022
medline: 19 7 2022
Statut: epublish

Résumé

Erythropoietin-stimulating agents (ESAs) have revolutionized anemia treatment in end-stage renal disease (ESRD), but ESA resistance is increasingly identified. Secondary hyperparathyroidism (SHP) is one cause of ESA resistance. We describe a patient with ESA-resistant, transfusion-dependent anemia and mild SHP with remodeling and reticulin fibrosis on bone marrow biopsy, all of which resolved with stricter SHP management. We identified 64 patients with anemia, ESRD, and bone marrow biopsy. The parathyroid hormone (PTH) range for bony remodeling was 183-16,161.9 pg/ml versus 90.8-3283 pg/ml. The PTH range for fibrotic changes was 183-2487 pg/ml versus 90.8-16,161.9 pg/ml. We found no clear PTH range predictive for bone marrow changes.

Identifiants

pubmed: 35846199
doi: 10.1002/jha2.316
pii: JHA2316
pmc: PMC9176131
doi:

Types de publication

Journal Article

Langues

eng

Pagination

159-162

Informations de copyright

© 2021 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.

Déclaration de conflit d'intérêts

All authors had no conflicts of interest to declare.

Références

Clin J Am Soc Nephrol. 2009 Jan;4(1):234-41
pubmed: 19056615
Nephrol Ther. 2011 Jul;7(4):229-36
pubmed: 21353659
Nephron. 1998;78(1):28-32
pubmed: 9453400
Blood Purif. 2010;29(1):1-12
pubmed: 19816014
Am J Kidney Dis. 2018 Mar;71(3):423-435
pubmed: 29336855
N Engl J Med. 1993 Jan 21;328(3):171-5
pubmed: 8417383
Arch Intern Med. 1979 Aug;139(8):889-91
pubmed: 464702
Arch Intern Med. 1978 Nov;138(11):1650-2
pubmed: 718313
Arch Intern Med. 1974 Nov;134(5):883-8
pubmed: 4613310
Braz J Med Biol Res. 2018;51(7):e7288
pubmed: 29742267
J Am Soc Nephrol. 2012 Oct;23(10):1631-4
pubmed: 22935483
PLoS One. 2016 Oct 20;11(10):e0164865
pubmed: 27764168

Auteurs

Bilal Ashraf (B)

Division of Hematology and Oncology Department of Internal Medicine University of Texas Southwestern Medical Center Dallas Texas USA.

Taha Bat (T)

Division of Hematology and Oncology Department of Internal Medicine University of Texas Southwestern Medical Center Dallas Texas USA.

Olga K Weinberg (OK)

Department of Pathology Hematopathology Section University of Texas Southwestern Medical Center Dallas Texas USA.

Orson W Moe (OW)

Division of Nephrology Department of Internal Medicine University of Texas Southwestern Medical Center Dallas Texas USA.
Charles and Jane Pak Center for Mineral Metabolism and Clinical Research University of Texas Southwestern Medical Center Dallas Texas USA.

Ibrahim Ibrahim (I)

Division of Hematology and Oncology Department of Internal Medicine University of Texas Southwestern Medical Center Dallas Texas USA.

Classifications MeSH